Development of an HPLC method for simultaneous analysis of five antineoplastic agents

Applied Occupational and Environmental Hygiene

Volumn 18, Issue 2, 2003, Pages 109-119

  Larson, Rodney R ^a   Khazaeli, M B ^b   Dillon, H Kenneth ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Antineoplastics; Cyclophosphamide; Doxorubicin; Fluorouracil; HPLC Analysis; Ifosfamide; Paclitaxel

Indexed keywords

ACETONITRILE; ADRICIL; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; IFOSFAMIDE; PACLITAXEL; WATER;

ANALYTIC METHOD; ARTICLE; CALIBRATION; CANCER CENTER; DRUG DETERMINATION; FLOW RATE; HEALTH CARE PERSONNEL; HEALTH HAZARD; OUTPATIENT DEPARTMENT; PH; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRAVIOLET RADIATION;

AMBULATORY CARE FACILITIES; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HEALTH PERSONNEL; HOSPITALS; HUMANS; OCCUPATIONAL EXPOSURE; RISK ASSESSMENT;

EID: 0345505698     PISSN: 1047322X     EISSN: None     Source Type: Journal    
DOI: 10.1080/10473220301432     Document Type: Article

References (49)

1. Reich, S.D.: Antineoplastic Agents as Potential Carcinogens: Are Nurses and Pharmacists at Risk? Cancer Nursing 6:500-502 (1981).
2. Sessink, P.J.M.; Boer, K.A.; Scheefhals, A.P.H.; et al.: Occupational Exposure to Antineoplastic Agents at Several Departments in a Hospital: Environmental Contamination and Excretion of Cyclophosphamide and Ifosfamide in Urine of Exposed Workers. Int Arch Occup Environ Health 64:105-112 (1992).
3. Connor, T.H.; Anderson, R.W.; Sessink, P.J.M.; et al.: Surface Contamination with Antineoplastic Agents in Six Cancer Treatment Centers in Canada and the United States. Am J Health-Syst Pharm 56:1427-1432 (1999).
4. Roets, P.: Reverse-Phase HPLC for Determination of Cyclophosphamide Collected on Teflon Filters. Bristol-Myers Squibb, New Brunswick, NJ (1993).
5. Roets, P.: Reverse-Phase HPLC Determination of Taxol in Dust Samples Collected on Teflon Filters. Bristol-Myers Squibb, New Brunswick, NJ (1993).
6. Brune, D.K.; Edling, C.: Occupational Hazards in the Health Professions. CRC Press, Boca Raton, FL (1989).
7. Chaff, L.E: Safety Guide for Healthcare Institutions, 4th ed., pp. 33-46, chap. 4. Hospital Publishing, Chicago (1989).
8. Christensen, C.J.; Lemasters, G.K.; Wakeman, M.A.: Work Practices and Policies of Hospital Pharmacists Preparing Antineoplastic Agents. J Occup Med 32:508-512 (1990).
9. Dollinger, M.; Rosenbaum, E.H.; Cable, G.: Everyone's Guide to Cancer Therapy, pp. 52-61. Somerville House Books, Kansas City, MO (1991).
10. Johnson, K.A.; Walker, N.F.: Combined Services of a Community Hospital and Clinic to Provide Antineoplastic Drugs for Outpatients. Am J Hosp Pharm 41:94-98 (1984).
11. U.S. Department of Labor, Occupational Safety and Health Administration: Controlling Occupational Exposure to Hazardous Drugs, Chapter 21, OSHA Instruction CPL 2-2.20B CH-4, April 14. OSHA, Washington, DC (1995).
12. U.S. Department of Labor, Occupational Safety and Health Administration: Controlling Occupational Exposure to Hazardous Drugs. OSHA Technical Manual - Section VI; Chapter 2. OSHA, Washington, DC (1998).
13. Benedict, W.F.; Baker, M.S.; Haroun, L.; et al.: Mutagenicity of Cancer Chemotherapeutic Agents in the Salmonella/Microsome Test. Cancer 37:2203-2213 (1977).
14. Harris, C.C.: The Carcinogenicity of Anticancer Drugs: A Hazard in Man. Cancer 37:1014-1023 (1976).
15. International Agency for Research on Cancer: Evaluation of the Carcinogenic Risk of Chemicals in Humans: IARC Monographs, Volumes 1-29. IARC, Lyon, France (1982).
16. Kolmodin-Hedman, B.; Hartvig, P.; Sorsa, M.; et al.: Occupational Handling of Cytostatic Drugs. Arch Toxicol 54:25-33 (1983).
17. Jochimsen, P.R.: Handling of Cytotoxic Drugs by Healthcare Workers: A Review of the Risks of Exposure. Drug Safety 7(5):374-380 (1992).
18. Physicians' Desk Reference 1999, 53rd ed. Medical Economics Co., Inc., Montvale, NJ (1999).
19. Mead Johnson Oncology Products: July 1998, Cytoxan (Cyclophosphamide) Rx Information Sheet. Bristol-Myers Squibb Co., Princeton, NJ (1998).
20. Harman, J.G.; Gilman, A.G.; Limbird, L.E.; eds.: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed., McGraw-Hill, Health Professions Division, New York (1996).
21. International Agency for Research on Cancer: Chemicals and Industrial Processes Associated with Cancer in Humans: IARC Monographs, Volumes 1-20. IARC, Lyon, France (1979).
22. International Agency for Research on Cancer: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Overall Evaluations of Carcinogenicity: And Updating of IARC Monographs Vols. 1 to 42. IARC, Lyon, France (1997).
23. International Agency for Research on Cancer: Resource on World Wide Web, IARC Home Page. http://www.iarc.fr. Accessed July and September (1999).
24. Sorsa, M.; Pyy, L.; Salomaa, S.; et al.: Biological and Environmental Monitoring of Occupational Exposure to Cyclophosphamide in Industry and Hospitals. Mut Res 204:465-479 (1988).
25. Purdom, C.E.: Mutagenic Effects of Nitrogen Mustard Derivative of Azobenzene Compounds in Drosophilia melanogaster. Biochem Pharmacol 5:206-218 (1960).
26. Toledo, T.M.; Harper, R.C.; Moser, R.H.: Fetal Effects During Cyclophosphamide and Irradiation Therapy. Ann Intern Med 74:87-91 (1971).
27. Vahlsing, H.L.; Feringa, E.R.; Britten, A.G.; et al.: Dental Abnormalities in Rats After Large Dose of Cyclophosphamide. Cancer Res 35:2199-2202 (1975).
28. McDevitt, J.J.; Lees, P.S.J.; McDiarmid, M.A.: Exposure of Hospital Pharmacists and Nurses to Antineoplastic Agents. J Occup Med 35:57-60 (1993).
29. Sessink, P.J.M.; Kroese, E.D.; van Kranen, H.J.; et al.: Cancer Risk Assessment for Health Care Workers Occupationally Exposed to Cyclophosphamide. Arch Environ Health 67:317-323 (1995).
30. Zheng, J.J.; Chan, K.K.; Muggia, E: Pre-Clinical Pharmacokinetics and Stability of Isophosphoramide Mustard. Cancer Chemo Pharmacol 33:391-398 (1994).
31. IFEX (ifosfamide) Rx information sheet. Mead Johnson Oncology Products, Princeton, NJ (1997).
32. Adrucil (5-Fluorouracil Injection, USP) Rx information sheet. Pharmacia & Upjohn Company, Kalamazoo, MI (1997).
33. Doxorubicin HCl for Injection Rx information sheet. Ben Venue Laboratories, Bedford, OH (1998).
34. Stewart, J.T.; Warren, F.W.; King, D.T.; et al.: Stability of Ondansetron Hydrochloride, Doxorubicin Hydrochloride, and Dacarbazine or Vincristine Sulfate in Elastomeric Portable Infusion Devices and Polyvinyl Chloride Bags. Am J Health-Syst Pharm 54:915-920 (1997).
35. Chan, K.C.; Alvarado, A.B.; McGuire, M.T.; et al.: High-Performance Liquid Chromatography and Micellar Electrokinetic Chromatography of Taxol and Related Taxanes from Bark and Needle Extracts of the Taxus Species. J Chromatography B 657:301-306 (1994).
36. Taxol (Paclitaxel) Rx information sheet. Mead Johnson Oncology Products, Princeton, NJ (1998).
37. Sessink, P.J.M.; Bos, R.P.: Drugs Hazardous to Healthcare Workers: Evaluation of Methods for Monitoring Occupational Exposure to Cytostatic Drugs. Drug Safety 20(4):347-349 (1999).
38. Baker, E.S.; Connor, T.H.: Review Article: Monitoring Occupational Exposure to Cancer Chemotherapy Drugs. Am J Health-Syst Pharm 53:2713-2723 (1996).
39. Hansen, J.; Olsen, J.H.: Cancer Morbidity Among Danish Female Pharmacy Technicians. Scand J Work Environ Health 20:22-26 (1994).
40. McDiarmid, M.A.; Egan, T.; Furio, M.; et al.: Sampling for Airborne Fluorouracil in a Hospital Drug Preparation Area. Am J Hosp Pharm 43:1942-1945 (1988).
41. Neal, A.D.; Wadden, R.A.; Chiou, W.L.: Exposure of Hospital Workers to Air-Borne Antineoplastic Agents. Am J Hosp Pharm 40:597-601 (1983).
42. Pyy, L.; Sorsa, M.; Hakala, E.: Ambient Monitoring of Cyclophosphamide in Manufacture and Hospitals. Am Indus Hyg Assoc J 49:314-317 (1988).
43. Volk, K.J.; Hill, S.E.; Kerns, E.H.; et al.: Profiling Degradants of Paclitaxel Using Liquid Chromatography - Mass Spectrometry and Liquid Chromatography - Tandem Mass Spectrometry Substructural Techniques. J Chromat B 696:99-115 (1997).
44. Stiles, M.L.; Allen Jr, L.V.; Prince, S.J.: Stability of Deferoxamine Mesylate, Floxuridine, Fluorouracil, Hydromorphon Hydrochloride, Lorazepam, Midazolam Hydrochloride in Polypropylene Infusion-Pump Syringes. Am J Health-Syst Pharm 53: 1583-1588 (1996).
45. Shao, L.K.; Locke, D.C.: Determination of Paclitaxel and Related Taxanes in Bulk Drug and Injectable Dosage Forms by Reversed Phase Liquid Chromatography. Anal Chem 69:2008-2016 (1997).
46. Rosner B.: Fundamentals of Statistics, 3rd ed. PWS-Kent Publishing, Boston (1990).
47. Benvenuto, J.A.; Connor, T.H.; Monteith, D.K.; et al.: Degradation and Inactivation of Antitumor Drugs. J Pharm Sci 82:988-991 (1993).
48. Sessink, P.J.M.; deRoos, J.H.C.; Pierik, F.H.; et al.: Occupational Exposure of Animal Caretakers to Cyclophosphamide. J Occup Med 35:47-52 (1993).
49. Selevan, S.G.; Lindbolm, M.L.; Hornung, R.W.; et al.: A Study of Occupational Exposure to Antineoplastic Drugs and Fetal Loss in Nurses. N Engl J Med 313:1173-1178 (1985).